Logo
x

Search

Subscribe Now

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) Receives the US FDA’s Approval to Treat NASH with Liver Fibrosis

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) Receives the US FDA’s Approval to Treat NASH with Liver Fibrosis

  • March 18, 2024
Madrigal Pharmaceuticals Reports the EMA’s Validation for the MAA of Resmetirom to Treat NASH/MASH with Liver Fibrosis

Madrigal Pharmaceuticals Reports the EMA’s Validation for the MAA of Resmetirom to Treat NASH/MASH with Liver Fibrosis

  • March 6, 2024
Madrigal Pharmaceuticals Reports the Results of Resmetirom in P-III Trial for the Treatment of NASH Patients

Madrigal Pharmaceuticals Reports the Results of Resmetirom in P-III Trial for the Treatment of NASH Patients

  • February 9, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.